New Manufacturing Process Patent for Ox-1

AI SummaryClose X

TheraCryf plc has filed a new process patent for its lead asset, Ox-1, a selective orexin-1 receptor antagonist for addiction, which, if granted, could extend commercial exclusivity to 2046, significantly beyond the existing composition of matter patent. This filing follows successful manufacturing optimization and scale-up, identifying novel efficiency improvements. Process patents create an additional barrier to generic competition by requiring alternative manufacturing routes to avoid infringement, strengthening the company's intellectual property estate as the program advances towards clinical readiness later in 2026. This strategic move aims to maximize the long-term commercial value and partnering potential of the Ox-1 program.

Disclaimer*

UK 100